How do we sequence and combine novel agent-based therapies in CLL?
Bringing minimal residual disease (MRD) measurement to the clinic
The future of immunotherapy in multiple myeloma
Hearn Cho et al.
Interferons: a promising potential therapy for MPN
Bendamustine plus rituximab vs. standard therapy for advanced CLL